The stock is tantalizing at $1.30 on February 20 2008 against a 52-week range of $4.60-0.75. There is strong stock investment logic behind this enticing trend as the management chalks up regulatory clearances in the most strategic health care markets. The company appears set to become a part of standard preventive care for all people at risk of heart failure.
The company is involved in the non-invasive diagnosis of serious heart conditions. This is a key growth area of the preventive healthcare market all over the world. Obesity, diabetes, and sedentary lifestyles mean that increasing numbers of people are at risks of developing cardiac problems. Older methods of detecting potentially fatal heart diseases early have either not been comprehensive, or have involved relatively expensive surgical procedures. This company has technology to monitor the electrical activity of heart beats to help physicians determine if patients are at risk of Sudden Cardiac Death. It has a proprietary system to monitor variations of no more than a millionth of a volt. The company’s know-how has strong support in scientific literature.
Japan and the European Union have followed the US Food and Drug Administration in granting approvals to the company to commence sales in their jurisdictions. That is why the company appears on course to profits in the near future. Major US health insurance companies have joined Medicare in agreeing to reimburse costs of tests using this company’s equipment for patients at risk of falling prey to certain cardiac emergencies. The latter causes more than 400 thousand deaths annually in the United States alone.
Let us hear your thoughts below: